Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$29.34M+186.49%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Xingjuan Chao
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 327
- Beta
- 0.86
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 14.33
Financials
Revenue
$29.34M+186.5%Net Income
$-21.35MEBITDA
$-20.84MFree Cash Flow
$-13.83MEPS (diluted)
$-0.55Shares Outstanding (diluted)
38.50M+65.1%Operating Expenses
$46.89MCash & Debt
$117.47MRevenue by Segment (annual)
$89.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $89.06M | $-53.41M | $-1.46 |
| 2024 | $65.44M | $-40.45M | $-1.13 |
| 2023 | $45.23M | $-29.46M | $-1.26 |
| 2022 | $25.92M | $-37.16M | $-1.59 |
Valuation
CBLLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (12)
- Newsfool.com·5h ago·Positive
CeriBell: 3 Key Takeaways for Long-Term Investors Full-year 2026 revenue guidance rose to $115 million to $117 million. CeriBell expanded its active account base by 35 hospital accounts.
View source ↗ - Newszacks.com·19d ago·Negative
CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.37 per share a year ago.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·19d ago·Negative
Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics The headline numbers for CeriBell, Inc. (CBLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
CeriBell Q3 Earnings Call Highlights CeriBell NASDAQ: CBLL reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring Solution and introduce its next-generation Omni hardware platform in 2027.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the commercial launch of its delirium monitoring solution on its point-of-care brain monitoring platform.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
…cipate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York C…
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push CeriBell NASDAQ: CBLL outlined its plans to expand its brainwave-monitoring platform beyond seizure detection, pointing to new products for delirium, pediatric patients and eventually stroke as it continues to build its hospital customer base.
View source ↗ - Newsseekingalpha.com·103d ago·Positive
CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·104d ago·Neutral
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·104d ago·Negative
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.38 per share a year ago.
View source ↗ - Newsmarketbeat.com·104d ago·Neutral
CeriBell Q2 Earnings Call Highlights CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at existing hospital accounts and continued customer additions supported results. The company also raised its full-year revenue outlook and outlined plans to commercially launch its delirium-monitoring solution later this year.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $-0.50 per share
Typical surprise +5.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.55 vs $-0.51miss
- Mon, Aug 10$-0.51 vs $-0.47miss
- Mon, May 11$-0.52 vs $-0.39miss
- Tue, Feb 24$-0.36 vs $-0.43beat
- Tue, Nov 4$-0.37 vs $-0.43beat
- Tue, Aug 5$-0.38 vs $-0.40beat
Estimates and results for CBLL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CBLL officers and directors.
- Bought
- —
- Sold
- $11.3m
0 trades
35 trades
- Taylor Joseph Michaelsold
- Woo Raymondsold
- Woo Raymondsold
- Chao Xingjuansold
- Blumberg Scottsold
- Foehr Davidsold
- Foehr Davidsold
- Woo Raymondsold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CBLL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
